XFRA CAPITAL ADJUSTMENT INFORMATION

XFRA CAPITAL ADJUSTMENT INFORMATION - 02.09.2024

Das Instrument MSPA MA0000011488 ITISSALAT AL-MA. INH.DH 6 EQUITY wird cum Kapitalmassnahme gehandelt am 02.09.2024 und ex Kapitalmassnahme am 03.09.2024
The instrument MSPA MA0000011488 ITISSALAT AL-MA. INH.DH 6 EQUITY is traded cum capital adjustment on 02.09.2024 and ex capital adjustment on 03.09.2024

Das Instrument TG4 BE0003846632 OXURION N.V. EQUITY wird cum Kapitalmassnahme gehandelt am 02.09.2024 und ex Kapitalmassnahme am 03.09.2024
The instrument TG4 BE0003846632 OXURION N.V. EQUITY is traded cum capital adjustment on 02.09.2024 and ex capital adjustment on 03.09.2024

Das Instrument 5LH0 SE0021181559 GUARD THERAPEUTICS INT.AB EQUITY wird ex Kapitalmassnahme gehandelt am 02.09.2024
The instrument 5LH0 SE0021181559 GUARD THERAPEUTICS INT.AB EQUITY is traded ex capital adjustment on 02.09.2024

Das Instrument HQ10 US00211Y5069 ARCA BIOPHARMA DL-,01 EQUITY wird cum Kapitalmassnahme gehandelt am 02.09.2024 und ex Kapitalmassnahme am 03.09.2024
The instrument HQ10 US00211Y5069 ARCA BIOPHARMA DL-,01 EQUITY is traded cum capital adjustment on 02.09.2024 and ex capital adjustment on 03.09.2024

Das Instrument FET KYG3307Z1090 FAR EAST CONS. INTL HD-10 EQUITY wird cum Kapitalmassnahme gehandelt am 02.09.2024 und ex Kapitalmassnahme am 03.09.2024
The instrument FET KYG3307Z1090 FAR EAST CONS. INTL HD-10 EQUITY is traded cum capital adjustment on 02.09.2024 and ex capital adjustment on 03.09.2024

Das Instrument 4QI KYG982771092 XTEP INTL HOL.REGS HD-,01 EQUITY wird cum Kapitalmassnahme gehandelt am 02.09.2024 und ex Kapitalmassnahme am 03.09.2024
The instrument 4QI KYG982771092 XTEP INTL HOL.REGS HD-,01 EQUITY is traded cum capital adjustment on 02.09.2024 and ex capital adjustment on 03.09.2024

Das Instrument 6LJ US5768101058 MATINAS BIOPH.HLD.DL-,001 EQUITY wird cum Kapitalmassnahme gehandelt am 02.09.2024 und ex Kapitalmassnahme am 03.09.2024
The instrument 6LJ US5768101058 MATINAS BIOPH.HLD.DL-,001 EQUITY is traded cum capital adjustment on 02.09.2024 and ex capital adjustment on 03.09.2024

Das Instrument M5L GB00B0MT3Y97 MATTIOLI WOODS PLC LS-,01 EQUITY wird cum Kapitalmassnahme gehandelt am 02.09.2024 und ex Kapitalmassnahme am 03.09.2024
The instrument M5L GB00B0MT3Y97 MATTIOLI WOODS PLC LS-,01 EQUITY is traded cum capital adjustment on 02.09.2024 and ex capital adjustment on 03.09.2024

Das Instrument EJ7 AU000000ERA9 ENERGY RES. A EQUITY wird ex Kapitalmassnahme gehandelt am 02.09.2024
The instrument EJ7 AU000000ERA9 ENERGY RES. A EQUITY is traded ex capital adjustment on 02.09.2024

Zeit	Aktuelle Nachrichten
Mo	ENERGY RESOURCES OF AUSTRALIA LIMITED: Appendix 3Y - Justin Carey
Mo	ENERGY RESOURCES OF AUSTRALIA LIMITED: Appendix 3Y - Alfie Grigg
26.03.	ENERGY RESOURCES OF AUSTRALIA LIMITED: Appendix 4G
26.03.	ENERGY RESOURCES OF AUSTRALIA LIMITED: 2024 Annual Report
24.03.	ENERGY RESOURCES OF AUSTRALIA LIMITED: Annual General Meeting Information

Zeit

Aktuelle Nachrichten

ENERGY RESOURCES OF AUSTRALIA LIMITED: Appendix 3Y - Justin Carey

ENERGY RESOURCES OF AUSTRALIA LIMITED: Appendix 3Y - Alfie Grigg

26.03.

ENERGY RESOURCES OF AUSTRALIA LIMITED: Appendix 4G

26.03.

ENERGY RESOURCES OF AUSTRALIA LIMITED: 2024 Annual Report

24.03.

ENERGY RESOURCES OF AUSTRALIA LIMITED: Annual General Meeting Information

Zeit	Aktuelle Nachrichten
25.03.	FE CONSORT INTL Hacked, Involving 250GB of Data
07.03.	FE CONSORT INTL Signs Heads of Agreement with CTFE & The Star for Australian Projects
07.03.	FE CONSORT INTL (00035): INSIDE INFORMATION ENTERING INTO HEADS OF AGREEMENT WITH THE STAR
28.02.	FE CONSORT INTL (00035): DISCLOSEABLE TRANSACTION IN RELATION TO THE DISPOSAL OF SHARES IN BC INVESTMENT GROUP HOLDINGS LIMITED
25.02.	AMTD IDEA Group: AMTD Successfully Reached a Strategic Partnership With the Far East Consortium for the UK	AMTD IDEA Group ("AMTD"; NYSE: AMTD; SGX: HKB) has entered into a strategic partnership with Far East Consortium International Limited ("FEC", 0035.HK) for the UK to drive forward the future of the... ► Artikel lesen

Zeit

Aktuelle Nachrichten

25.03.

FE CONSORT INTL Hacked, Involving 250GB of Data

07.03.

FE CONSORT INTL Signs Heads of Agreement with CTFE & The Star for Australian Projects

07.03.

FE CONSORT INTL (00035): INSIDE INFORMATION ENTERING INTO HEADS OF AGREEMENT WITH THE STAR

28.02.

FE CONSORT INTL (00035): DISCLOSEABLE TRANSACTION IN RELATION TO THE DISPOSAL OF SHARES IN BC INVESTMENT GROUP HOLDINGS LIMITED

25.02.

AMTD IDEA Group: AMTD Successfully Reached a Strategic Partnership With the Far East Consortium for the UK

AMTD IDEA Group ("AMTD"; NYSE: AMTD; SGX: HKB) has entered into a strategic partnership with Far East Consortium International Limited ("FEC", 0035.HK) for the UK to drive forward the future of the...
► Artikel lesen

Zeit	Aktuelle Nachrichten
25.03.	Guard Therapeutics International AB: Two-thirds of patients enrolled in Guard Therapeutics' Phase 2b POINTER study	Guard Therapeutics announced today that it has reached another key milestone in its ongoing clinical development program. Two-thirds of the approximately 160 planned patients have now been enrolled... ► Artikel lesen
14.03.	XFRA CAPITAL ADJUSTMENT INFORMATION - 14.03.2025	Das Instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY wird cum Kapitalmassnahme gehandelt am 14.03.2025 und ex Kapitalmassnahme am 17.03.2025 The instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY... ► Artikel lesen
10.03.	Guard Therapeutics International AB: The Board of Directors of Guard Therapeutics has resolved on a previously announced rights issue of approximately SEK 150 million	THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen
27.02.	Guard Therapeutics International AB: Guard Therapeutics announces positive outcome from first independent safety data review in Phase 2b POINTER study	Guard Therapeutics announced today that an independent Data Safety Monitoring Committee (DSMC) has completed its first planned review of safety data and has recommended that the Phase 2b clinical study... ► Artikel lesen

Zeit

Aktuelle Nachrichten

25.03.

Guard Therapeutics International AB: Two-thirds of patients enrolled in Guard Therapeutics' Phase 2b POINTER study

Guard Therapeutics announced today that it has reached another key milestone in its ongoing clinical development program. Two-thirds of the approximately 160 planned patients have now been enrolled...
► Artikel lesen

14.03.

XFRA CAPITAL ADJUSTMENT INFORMATION - 14.03.2025

Das Instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY wird cum Kapitalmassnahme gehandelt am 14.03.2025 und ex Kapitalmassnahme am 17.03.2025 The instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY...
► Artikel lesen

10.03.

Guard Therapeutics International AB: The Board of Directors of Guard Therapeutics has resolved on a previously announced rights issue of approximately SEK 150 million

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA...
► Artikel lesen

27.02.

Guard Therapeutics International AB: Guard Therapeutics announces positive outcome from first independent safety data review in Phase 2b POINTER study

Guard Therapeutics announced today that an independent Data Safety Monitoring Committee (DSMC) has completed its first planned review of safety data and has recommended that the Phase 2b clinical study...
► Artikel lesen

Zeit	Aktuelle Nachrichten
Mo	Maroc Telecom and Inwi unite for 5G and fibre optic expansion in Morocco
Fr	Maroc Telecom and Inwi Announce $460 Million Joint Investment for 5G Rollout in Morocco
Fr	XFRA MSPA: WIEDERAUFNAHME/RESUMPTION	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen
Do	Maroc Telecom, INWI partner to accelerate deployment of fiber optics networks, 5G technology across Morocco
Do	XFRA MSPA: AUSSETZUNG/SUSPENSION	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILITISSALAT AL-MA.... ► Artikel lesen

Zeit

Aktuelle Nachrichten

Maroc Telecom and Inwi unite for 5G and fibre optic expansion in Morocco

Maroc Telecom and Inwi Announce $460 Million Joint Investment for 5G Rollout in Morocco

XFRA MSPA: WIEDERAUFNAHME/RESUMPTION

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen

Maroc Telecom, INWI partner to accelerate deployment of fiber optics networks, 5G technology across Morocco

XFRA MSPA: AUSSETZUNG/SUSPENSION

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILITISSALAT AL-MA....
► Artikel lesen

Zeit	Aktuelle Nachrichten
Mo	Matinas BioPharma Holdings, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
11.03.	Matinas BioPharma Holdings, Inc.: Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
11.03.	Matinas BioPharma Holdings, Inc. - 8-K, Current Report
13.02.	Matinas BioPharma announces agreement for the acquisition of preferred stock
13.02.	Matinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

Zeit

Aktuelle Nachrichten

Matinas BioPharma Holdings, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

11.03.

Matinas BioPharma Holdings, Inc.: Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

11.03.

Matinas BioPharma Holdings, Inc. - 8-K, Current Report

13.02.

Matinas BioPharma announces agreement for the acquisition of preferred stock

13.02.

Matinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

Zeit	Aktuelle Nachrichten
19.11.24	Mattioli Woods: Profit slashed at wealth manager as it quit London
02.09.24	XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.09.2024	The following instruments on Boerse Frankfurt do have their last trading day on 02.09.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.09.2024ISIN NameBE0003846632 OXURION... ► Artikel lesen
02.09.24	XFRA CAPITAL ADJUSTMENT INFORMATION - 02.09.2024	Das Instrument MSPA MA0000011488 ITISSALAT AL-MA. INH.DH 6 EQUITY wird cum Kapitalmassnahme gehandelt am 02.09.2024 und ex Kapitalmassnahme am 03.09.2024 The instrument MSPA MA0000011488 ITISSALAT AL-MA.... ► Artikel lesen

Zeit

Aktuelle Nachrichten

19.11.24

Mattioli Woods: Profit slashed at wealth manager as it quit London

02.09.24

XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.09.2024

The following instruments on Boerse Frankfurt do have their last trading day on 02.09.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.09.2024ISIN NameBE0003846632 OXURION...
► Artikel lesen

02.09.24

XFRA CAPITAL ADJUSTMENT INFORMATION - 02.09.2024

Zeit	Aktuelle Nachrichten
09.03.	Oruka Therapeutics zeigt Fortschritte trotz Verlusten
07.03.	Stifel maintains Buy rating on Oruka Therapeutics stock, $49 target
07.03.	Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting	Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab... ► Artikel lesen
06.03.	Oruka Therapeutics, Inc. Q4 Loss Narrows
06.03.	ARCA biopharma GAAP EPS of -$0.49 misses by $0.08

Zeit

Aktuelle Nachrichten

09.03.

Oruka Therapeutics zeigt Fortschritte trotz Verlusten

07.03.

Stifel maintains Buy rating on Oruka Therapeutics stock, $49 target

07.03.

Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab...
► Artikel lesen

06.03.

Oruka Therapeutics, Inc. Q4 Loss Narrows

06.03.

ARCA biopharma GAAP EPS of -$0.49 misses by $0.08

Zeit	Aktuelle Nachrichten
Do	OXURION: Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC	Leuven, BELGIUM - March 27, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency... ► Artikel lesen
Do	OXURION: Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC	Leuven, BELGIUM - March 27, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency... ► Artikel lesen
24.03.	OXURION: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas	Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital... ► Artikel lesen
18.03.	OXURION: Oxurion signs a letter of intent for the planned acquisition of a biometrics-focused CRO	Louvain, BELGIUM - March 18, 2025 - 6:30 PM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces the signing of a letter of intent (LOI) for... ► Artikel lesen
18.03.	OXURION: Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC	Leuven, BELGIUM - March 18, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency... ► Artikel lesen

Zeit

Aktuelle Nachrichten

OXURION: Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Leuven, BELGIUM - March 27, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen

OXURION: Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC

24.03.

OXURION: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital...
► Artikel lesen

18.03.

OXURION: Oxurion signs a letter of intent for the planned acquisition of a biometrics-focused CRO

Louvain, BELGIUM - March 18, 2025 - 6:30 PM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces the signing of a letter of intent (LOI) for...
► Artikel lesen

18.03.

OXURION: Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Leuven, BELGIUM - March 18, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen

Zeit	Aktuelle Nachrichten
19.03.	Xtep's Stock Falls After Chinese Sportswear Brand Names Founder's Daughter as New CFO
18.03.	XTEP INT'L Annual NP Up 20% Setting New High; Final + Spec. DPS HKD54.2 Cents
18.03.	XTEP INT'L (01368): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2024
18.03.	XTEP INT'L (01368): 2024 ANNUAL RESULTS ANNOUNCEMENT
18.03.	XTEP INT'L (01368): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

Zeit

Aktuelle Nachrichten

19.03.

Xtep's Stock Falls After Chinese Sportswear Brand Names Founder's Daughter as New CFO

18.03.

XTEP INT'L Annual NP Up 20% Setting New High; Final + Spec. DPS HKD54.2 Cents

18.03.

XTEP INT'L (01368): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2024

18.03.

XTEP INT'L (01368): 2024 ANNUAL RESULTS ANNOUNCEMENT

18.03.

XTEP INT'L (01368): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

Unternehmen / Aktien	Kurs	%
ENERGY RESOURCES OF AUSTRALIA LIMITED	0,001	-33,33 %
FAR EAST CONSORTIUM INTERNATIONAL LTD	0,084	0,00 %
GUARD THERAPEUTICS INTERNATIONAL AB	1,360	+0,74 %
MAROC TELECOM	7,200	0,00 %
MATINAS BIOPHARMA HOLDINGS INC	0,054	0,00 %
MATTIOLI WOODS PLC	9,250	0,00 %
ORUKA THERAPEUTICS INC	11,200	+26,55 %
OXURION NV	0,100	0,00 %
XTEP INTERNATIONAL HOLDINGS LTD	0,620	+4,20 %

Unternehmen / Aktien

Kurs

ENERGY RESOURCES OF AUSTRALIA LIMITED

0,001

-33,33 %

FAR EAST CONSORTIUM INTERNATIONAL LTD

0,084

0,00 %

GUARD THERAPEUTICS INTERNATIONAL AB

1,360

+0,74 %

MAROC TELECOM